Founded by Dr. Mark Pruzanski in 2002, Intercept had previously raised about $45m from private investors, including Italy-based Genextra, US-based venture capital firm Visium and Jafco Life Science Investment, which raised about a quarter of its latest near Y240bn ($3bn) fund from corporations.

Intercept Pharmaceuticals, a US-based liver drugs maker based on work at Italy’s University of Perugia, has raised $30m in its series C round.

Venture capital firm OrbiMed Advisors led the C round, with Intercept’s majority investor, Genextra, also participating. Genextra was created in 2004 by a group of Italian entrepreneurs and financial institutions in partnership with leading scientists from the European Institute of Oncology (IEO) and has €96m in funds.

Founded by Dr. Mark Pruzanski in 2002, Intercept had previously raised about $45m from private investors, including Italy-based Genextra, US-based venture capital firm Visium and Jafco Life Science Investment, which raised about a quarter of its latest near Y240bn ($3bn) fund from corporations.

Intercept plans to use part of the money to fuel its phase III study in which its oral obeticholic acid (OCA) drug is under investigation as a second-line therapy for primary biliary cirrhosis, a rare condition…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?